Steve H. Thorne YOU? Author Swipe

Last 10y

1394 Novel oncolytic viral immunotherapy VET3-TGI displays enhanced systemic delivery and inhibits TGFb-signaling while augmenting type-1 immune response in the tumor Open

Steve H. Thorne · 2023

Background The clinical success of oncolytic viral immunotherapies will likely require development of technologies to achieve targeted intravenous delivery to the tumor bed, and the expression of novel therapeutic transgene combinations to…

Data from CNOB/ChrR6, a new prodrug enzyme cancer chemotherapy Open

Steve H. Thorne, Yoram Barak, Wenchuan Liang, Michael H. Bachmann, Jianghong Rao , et al. · 2023

We report the discovery of a new prodrug, 6-chloro-9-nitro-5-oxo-5H-benzo(a)phenoxazine (CNOB). This prodrug is efficiently activated by ChrR6, the highly active prodrug activating bacterial enzyme we have previously develope…

Supplemental Figures S1-5 from Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy Open

Juan J. Rojas, Padma Sampath, Weizhou Hou, Steve H. Thorne · 2023

Supplemental Figures S1-5. S1: isotype controls and ctla-4 effects on viral replication; S2: effects of anti-CD25; S3: B18R effects on Treg and NK cells; S4: gating for T-cells and NK cells; S5: effects of IFNg depletion

Supplementary Fig. from CNOB/ChrR6, a new prodrug enzyme cancer chemotherapy Open

Steve H. Thorne, Yoram Barak, Wenchuan Liang, Michael H. Bachmann, Jianghong Rao , et al. · 2023

Supplementary Fig. from CNOB/ChrR6, a new prodrug enzyme cancer chemotherapy

Data from Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy Open

Juan J. Rojas, Padma Sampath, Weizhou Hou, Steve H. Thorne · 2023

Purpose: Recent data from randomized clinical trials with oncolytic viral therapies and with cancer immunotherapies have finally recapitulated the promise these platforms demonstrated in preclinical models. Perhaps the greatest adva…

Data from Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy Open

Juan J. Rojas, Padma Sampath, Weizhou Hou, Steve H. Thorne · 2023

Purpose: Recent data from randomized clinical trials with oncolytic viral therapies and with cancer immunotherapies have finally recapitulated the promise these platforms demonstrated in preclinical models. Perhaps the greatest adva…

Data from CNOB/ChrR6, a new prodrug enzyme cancer chemotherapy Open

Steve H. Thorne, Yoram Barak, Wenchuan Liang, Michael H. Bachmann, Jianghong Rao , et al. · 2023

We report the discovery of a new prodrug, 6-chloro-9-nitro-5-oxo-5H-benzo(a)phenoxazine (CNOB). This prodrug is efficiently activated by ChrR6, the highly active prodrug activating bacterial enzyme we have previously develope…

Supplemental Figures S1-5 from Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy Open

Juan J. Rojas, Padma Sampath, Weizhou Hou, Steve H. Thorne · 2023

Supplemental Figures S1-5. S1: isotype controls and ctla-4 effects on viral replication; S2: effects of anti-CD25; S3: B18R effects on Treg and NK cells; S4: gating for T-cells and NK cells; S5: effects of IFNg depletion

Supplementary Fig. from CNOB/ChrR6, a new prodrug enzyme cancer chemotherapy Open

Steve H. Thorne, Yoram Barak, Wenchuan Liang, Michael H. Bachmann, Jianghong Rao , et al. · 2023

Supplementary Fig. from CNOB/ChrR6, a new prodrug enzyme cancer chemotherapy

Supplementary Methods from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans Open

Caroline J. Breitbach, Rozanne Arulanandam, Naomi De Silva, Steve H. Thorne, Richard B. Patt , et al. · 2023

Supplementary Methods PDF file - 44K, GLP toxicology study, In vivo imaging and mouse immunohistochemical analyses

Data from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans Open

Caroline J. Breitbach, Rozanne Arulanandam, Naomi De Silva, Steve H. Thorne, Richard B. Patt , et al. · 2023

Efforts to selectively target and disrupt established tumor vasculature have largely failed to date. We hypothesized that a vaccinia virus engineered to target cells with activation of the ras/MAPK signaling pathway (JX-594) could specific…

Supplementary Figure 2 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans Open

Caroline J. Breitbach, Rozanne Arulanandam, Naomi De Silva, Steve H. Thorne, Richard B. Patt , et al. · 2023

Supplementary Figure 2 PDF file - 144K, Bevacizumab reduces TK1 levels & blocks VEGF-mediated JX-594 sensitization in HUVECs, demonstrated by decreased transgene expression (GFP) and decreased burst size

Supplementary Figure 1 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans Open

Caroline J. Breitbach, Rozanne Arulanandam, Naomi De Silva, Steve H. Thorne, Richard B. Patt , et al. · 2023

Supplementary Figure 1 PDF file - 74K, VEGF- and FGF-2 stimulate vaccinia replication

Supplementary Table 1 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans Open

Caroline J. Breitbach, Rozanne Arulanandam, Naomi De Silva, Steve H. Thorne, Richard B. Patt , et al. · 2023

Supplementary Table 1 PDF file - 30K, Rabbit GLP toxicology study of intravenous JX-594

Supplementary Video 2 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans Open

Caroline J. Breitbach, Rozanne Arulanandam, Naomi De Silva, Steve H. Thorne, Richard B. Patt , et al. · 2023

Supplementary Video 2 MPG file - 1158K, 3-dimensional tumor model of 10 cm HCC tumor depicted in Fig. 4b (baseline; 5 days post JX-594 treatment). Beige = perfused; green = hypoperfused; red = necrotic

Supplementary Video 1 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans Open

Caroline J. Breitbach, Rozanne Arulanandam, Naomi De Silva, Steve H. Thorne, Richard B. Patt , et al. · 2023

Supplementary Video 1 MPG file - 708K, 3-dimensional tumor model of 10 cm HCC tumor depicted in Fig. 4a (baseline; prior to JX-594 treatment). Beige = perfused; green = hypoperfused; red = necrotic

Supplementary Figure 4 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans Open

Caroline J. Breitbach, Rozanne Arulanandam, Naomi De Silva, Steve H. Thorne, Richard B. Patt , et al. · 2023

Supplementary Figure 4 PDF file - 69K, Day 5 enhancement waterfall plot

Supplementary Figure 3 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans Open

Caroline J. Breitbach, Rozanne Arulanandam, Naomi De Silva, Steve H. Thorne, Richard B. Patt , et al. · 2023

Supplementary Figure 3 PDF file - 83K, Normal fibroblasts (GM38 cells) do not express VEGFR2 and are not sensitized to JX-594 infection upon incubation with VEGF

Supplementary Video 1 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans Open

Caroline J. Breitbach, Rozanne Arulanandam, Naomi De Silva, Steve H. Thorne, Richard B. Patt , et al. · 2023

Supplementary Video 1 MPG file - 708K, 3-dimensional tumor model of 10 cm HCC tumor depicted in Fig. 4a (baseline; prior to JX-594 treatment). Beige = perfused; green = hypoperfused; red = necrotic

Supplementary Video 2 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans Open

Caroline J. Breitbach, Rozanne Arulanandam, Naomi De Silva, Steve H. Thorne, Richard B. Patt , et al. · 2023

Supplementary Video 2 MPG file - 1158K, 3-dimensional tumor model of 10 cm HCC tumor depicted in Fig. 4b (baseline; 5 days post JX-594 treatment). Beige = perfused; green = hypoperfused; red = necrotic

Data from Definition of an Enhanced Immune Cell Therapy in Mice That Can Target Stem-Like Lymphoma Cells Open

Christopher H. Contag, Rachel Sikorski, Robert S. Negrin, Tobi Schmidt, Alice C. Fan , et al. · 2023

Current treatments of high-grade lymphoma often have curative potential, but unfortunately many patients relapse and develop therapeutic resistance. Thus, there remains a need for novel therapeutics that can target the residual cancer cell…

Supplementary Methods from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans Open

Caroline J. Breitbach, Rozanne Arulanandam, Naomi De Silva, Steve H. Thorne, Richard B. Patt , et al. · 2023

Supplementary Methods PDF file - 44K, GLP toxicology study, In vivo imaging and mouse immunohistochemical analyses

Supplementary Figures 1-3 from Definition of an Enhanced Immune Cell Therapy in Mice That Can Target Stem-Like Lymphoma Cells Open

Christopher H. Contag, Rachel Sikorski, Robert S. Negrin, Tobi Schmidt, Alice C. Fan , et al. · 2023

Supplementary Figures 1-3 from Definition of an Enhanced Immune Cell Therapy in Mice That Can Target Stem-Like Lymphoma Cells

Supplementary Figure 4 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans Open

Caroline J. Breitbach, Rozanne Arulanandam, Naomi De Silva, Steve H. Thorne, Richard B. Patt , et al. · 2023

Supplementary Figure 4 PDF file - 69K, Day 5 enhancement waterfall plot

Supplementary Figure 2 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans Open

Caroline J. Breitbach, Rozanne Arulanandam, Naomi De Silva, Steve H. Thorne, Richard B. Patt , et al. · 2023

Supplementary Figure 2 PDF file - 144K, Bevacizumab reduces TK1 levels & blocks VEGF-mediated JX-594 sensitization in HUVECs, demonstrated by decreased transgene expression (GFP) and decreased burst size

Supplementary Figures 1-3 from Definition of an Enhanced Immune Cell Therapy in Mice That Can Target Stem-Like Lymphoma Cells Open

Christopher H. Contag, Rachel Sikorski, Robert S. Negrin, Tobi Schmidt, Alice C. Fan , et al. · 2023

Supplementary Figures 1-3 from Definition of an Enhanced Immune Cell Therapy in Mice That Can Target Stem-Like Lymphoma Cells

Supplementary Table 1 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans Open

Caroline J. Breitbach, Rozanne Arulanandam, Naomi De Silva, Steve H. Thorne, Richard B. Patt , et al. · 2023

Supplementary Table 1 PDF file - 30K, Rabbit GLP toxicology study of intravenous JX-594

Data from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans Open

Caroline J. Breitbach, Rozanne Arulanandam, Naomi De Silva, Steve H. Thorne, Richard B. Patt , et al. · 2023

Efforts to selectively target and disrupt established tumor vasculature have largely failed to date. We hypothesized that a vaccinia virus engineered to target cells with activation of the ras/MAPK signaling pathway (JX-594) could specific…

Data from Definition of an Enhanced Immune Cell Therapy in Mice That Can Target Stem-Like Lymphoma Cells Open

Christopher H. Contag, Rachel Sikorski, Robert S. Negrin, Tobi Schmidt, Alice C. Fan , et al. · 2023

Current treatments of high-grade lymphoma often have curative potential, but unfortunately many patients relapse and develop therapeutic resistance. Thus, there remains a need for novel therapeutics that can target the residual cancer cell…

Supplementary Figure 1 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans Open

Caroline J. Breitbach, Rozanne Arulanandam, Naomi De Silva, Steve H. Thorne, Richard B. Patt , et al. · 2023

Supplementary Figure 1 PDF file - 74K, VEGF- and FGF-2 stimulate vaccinia replication

Fetching topic information...